Trials / Completed
CompletedNCT00877656
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Emergent BioSolutions · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.
Detailed description
The study is closed and all subjects have completed treatment. The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in subjects with non-cutaneous T cell lymphoma. The primary efficacy will be evaluated by time to relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HuMax-CD4 | Active treatment |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2006-01-01
- Completion
- 2008-12-01
- First posted
- 2009-04-08
- Last updated
- 2024-03-18
Source: ClinicalTrials.gov record NCT00877656. Inclusion in this directory is not an endorsement.